Nuvectis Pharma, Inc. (NVCT)
NASDAQ: NVCT · Real-Time Price · USD
6.08
+0.20 (3.40%)
Nov 21, 2025, 4:00 PM EST - Market closed
Nuvectis Pharma Employees
Nuvectis Pharma had 13 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
13
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,138,846
Market Cap
155.74M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 13 | 0 | - |
| Dec 31, 2023 | 13 | 2 | 18.18% |
| Dec 31, 2022 | 11 | 3 | 37.50% |
| Dec 31, 2021 | 8 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
NVCT News
- 17 days ago - CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights - GlobeNewsWire
- 5 weeks ago - Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - GlobeNewsWire
- 2 months ago - Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 3 months ago - Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900 - GlobeNewsWire
- 3 months ago - Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights - GlobeNewsWire
- 4 months ago - Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study - GlobeNewsWire
- 6 months ago - Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference - GlobeNewsWire
- 7 months ago - Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights - GlobeNewsWire